These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

850 related articles for article (PubMed ID: 35561224)

  • 41. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
    Sahin U; Muik A; Vogler I; Derhovanessian E; Kranz LM; Vormehr M; Quandt J; Bidmon N; Ulges A; Baum A; Pascal KE; Maurus D; Brachtendorf S; Lörks V; Sikorski J; Koch P; Hilker R; Becker D; Eller AK; Grützner J; Tonigold M; Boesler C; Rosenbaum C; Heesen L; Kühnle MC; Poran A; Dong JZ; Luxemburger U; Kemmer-Brück A; Langer D; Bexon M; Bolte S; Palanche T; Schultz A; Baumann S; Mahiny AJ; Boros G; Reinholz J; Szabó GT; Karikó K; Shi PY; Fontes-Garfias C; Perez JL; Cutler M; Cooper D; Kyratsous CA; Dormitzer PR; Jansen KU; Türeci Ö
    Nature; 2021 Jul; 595(7868):572-577. PubMed ID: 34044428
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans.
    Alsoussi WB; Malladi SK; Zhou JQ; Liu Z; Ying B; Kim W; Schmitz AJ; Lei T; Horvath SC; Sturtz AJ; McIntire KM; Evavold B; Han F; Scheaffer SM; Fox IF; Mirza SF; Parra-Rodriguez L; Nachbagauer R; Nestorova B; Chalkias S; Farnsworth CW; Klebert MK; Pusic I; Strnad BS; Middleton WD; Teefey SA; Whelan SPJ; Diamond MS; Paris R; O'Halloran JA; Presti RM; Turner JS; Ellebedy AH
    Nature; 2023 May; 617(7961):592-598. PubMed ID: 37011668
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
    Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
    mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants.
    Cui L; Li T; Xue W; Zhang S; Wang H; Liu H; Gu Y; Xia N; Li S
    Viruses; 2024 Jun; 16(6):. PubMed ID: 38932192
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants.
    Pishesha N; Harmand TJ; Rothlauf PW; Praest P; Alexander RK; van den Doel R; Liebeskind MJ; Vakaki MA; McCaul N; Wijne C; Verhaar E; Pinney W; Heston H; Bloyet LM; Pontelli MC; Ilagan MXG; Jan Lebbink R; Buchser WJ; Wiertz EJHJ; Whelan SPJ; Ploegh HL
    Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34654739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice.
    Wørzner K; Sheward DJ; Schmidt ST; Hanke L; Zimmermann J; McInerney G; Karlsson Hedestam GB; Murrell B; Christensen D; Pedersen GK
    EBioMedicine; 2021 Jan; 63():103197. PubMed ID: 33422991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():995235. PubMed ID: 36172368
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Protective immunity induced by an inhaled SARS-CoV-2 subunit vaccine.
    Elder E; Bangalore Revanna C; Johansson C; Wallin RPA; Sjödahl J; Winqvist O; Mirazimi A
    Vaccine; 2023 Jul; 41(32):4743-4751. PubMed ID: 37353452
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines.
    Sun C; Yuan RY; Xie C; Sun JF; Fang XY; Hu YS; Yu XH; Liu Z; Zeng MS; Kang YF
    J Virol; 2022 Jul; 96(13):e0038322. PubMed ID: 35699445
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein.
    Castro JT; Azevedo P; Fumagalli MJ; Hojo-Souza NS; Salazar N; Almeida GG; Oliveira LI; Faustino L; Antonelli LR; Marçal TG; Augusto M; Valiate B; Fiorini A; Rattis B; Ramos SG; Piccin M; Nonato OC; Benevides L; Magalhães R; Cassaro B; Burle G; Doro D; Kalil J; Durigon E; Salazar A; Caballero O; Santiago H; Machado A; Silva JS; da Fonseca F; Fernandes AP; Teixeira SR; Gazzinelli RT
    Nat Commun; 2022 Aug; 13(1):4831. PubMed ID: 35977933
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.
    de Alwis R; Gan ES; Chen S; Leong YS; Tan HC; Zhang SL; Yau C; Low JGH; Kalimuddin S; Matsuda D; Allen EC; Hartman P; Park KJ; Alayyoubi M; Bhaskaran H; Dukanovic A; Bao Y; Clemente B; Vega J; Roberts S; Gonzalez JA; Sablad M; Yelin R; Taylor W; Tachikawa K; Parker S; Karmali P; Davis J; Sullivan BM; Sullivan SM; Hughes SG; Chivukula P; Ooi EE
    Mol Ther; 2021 Jun; 29(6):1970-1983. PubMed ID: 33823303
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine.
    Gallais F; Gantner P; Planas D; Solis M; Bruel T; Pierre F; Soulier E; Rossolillo P; Fourati S; Sibilia J; Schwartz O; Fafi-Kremer S
    Front Immunol; 2022; 13():790212. PubMed ID: 35281046
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sex-biased immunogenicity of a mucosal subunit vaccine against SARS-CoV-2 in mice.
    Li J; Hsu KS; Howe SE; Hoang T; Xia Z; Berzofsky JA; Sui Y
    Front Immunol; 2024; 15():1386243. PubMed ID: 38835757
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systemic Neutralizing Antibodies and Local Immune Responses Are Critical for the Control of SARS-CoV-2.
    Chandrasekar SS; Phanse Y; Riel M; Hildebrand RE; Hanafy M; Osorio JE; Abdelgayed SS; Talaat AM
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746733
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
    Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
    J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mucosal SARS-CoV-2 vaccination of rodents elicits superior systemic T central memory function and cross-neutralising antibodies against variants of concern.
    O'Neill A; Mantri CK; Tan CW; Saron WAA; Nagaraj SK; Kala MP; Joy CM; Rathore APS; Tripathi S; Wang LF; St John AL
    EBioMedicine; 2024 Jan; 99():104924. PubMed ID: 38113758
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease.
    Yan J; Bangalore CR; Nikouyan N; Appelberg S; Silva DN; Yao H; Pasetto A; Weber F; Weber S; Larsson O; Höglund U; Bogdanovic G; Grabbe M; Aleman S; Szekely L; Szakos A; Tuvesson O; Gidlund EK; Cadossi M; Salati S; Tegel H; Hober S; Frelin L; Mirazimi A; Ahlén G; Sällberg M
    Mol Ther; 2024 Feb; 32(2):540-555. PubMed ID: 38213030
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern.
    Rudi E; Martin Aispuro P; Zurita E; Gonzalez Lopez Ledesma MM; Bottero D; Malito J; Gabrielli M; Gaillard E; Stuible M; Durocher Y; Gamarnik AV; Wigdorovitz A; Hozbor D
    Front Immunol; 2022; 13():1020159. PubMed ID: 36248791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.